公开(公告)号：US20180325884A1

公开(公告)日：2018-11-15

申请号：US16041067

申请日：2018-07-20

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  C07K16/22 ,  A61K47/38 ,  A61K9/00 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61M37/00 ,  A61K47/26 ,  A61K47/12 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20160206628A1

公开(公告)日：2016-07-21

申请号：US15001610

申请日：2016-01-20

Applicant: Clearside Biomedical, Inc.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/573 ,  A61K47/12 ,  A61K47/26 ,  A61K9/00 ,  A61K47/38

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20200030143A1

公开(公告)日：2020-01-30

申请号：US16591067

申请日：2019-10-02

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Rafael Victor ANDINO ,  Vladimir ZARNITSYN ,  Jesse YOO ,  Christopher John BROOKS ,  Trent John KAHUTE ,  Justin William ARSENAULT ,  David Jackson TRETTIN ,  Andrew Kent BAUER ,  Stephanie Elaine LEWIS

IPC: A61F9/00 ,  A61J1/20 ,  A61M5/34 ,  A61M5/31 ,  A61M37/00 ,  A61M5/20 ,  A61M5/32 ,  A61M5/48 ,  A61M5/46

Abstract: An apparatus includes a housing coupled to a medicament container, which is coupled to a needle. An injection assembly is disposed within the housing and includes an energy storage member and an actuation rod. A distal end portion of the actuation rod is disposed within the medicament container. The energy storage member can produce a force on a proximal end portion of the actuation rod sufficient to move the distal end portion of the actuation rod within the medicament container. This can convey at least a portion of a substance from the medicament container via the needle when a distal tip of the needle is disposed within a first region of a target location. The force is insufficient to move the distal end portion of the actuation rod within the medicament container when the distal tip of the needle is disposed within a second region of the target location.

公开(公告)号：US20180028358A1

公开(公告)日：2018-02-01

申请号：US15714441

申请日：2017-09-25

Applicant: Clearside Biomedical, Inc.

Inventor： Rafael Victor ANDINO ,  Vladimir ZARNITSYN ,  Jesse YOO ,  Christopher John BROOKS ,  Trent John KAHUTE ,  Justin William ARSENAULT ,  David Jackson TRETTIN ,  Andrew Kent BAUER ,  Stephanie Elaine LEWIS

IPC: A61F9/00 ,  A61M5/20 ,  A61M37/00 ,  A61M5/34 ,  A61M5/46 ,  A61M5/48 ,  A61J1/20 ,  A61M5/32

CPC classification number: A61F9/0017 ,  A61F2250/0007 ,  A61F2250/0069 ,  A61J1/201 ,  A61J1/2055 ,  A61J1/2096 ,  A61M5/2033 ,  A61M5/2053 ,  A61M5/31 ,  A61M5/3293 ,  A61M5/34 ,  A61M5/344 ,  A61M5/346 ,  A61M5/347 ,  A61M5/348 ,  A61M5/349 ,  A61M5/46 ,  A61M5/482 ,  A61M37/0015 ,  A61M2005/31508 ,  A61M2037/0023 ,  A61M2037/0061 ,  A61M2210/0612

Abstract: An apparatus includes a housing coupled to a medicament container, which is coupled to a needle. An injection assembly is disposed within the housing and includes an energy storage member and an actuation rod. A distal end portion of the actuation rod is disposed within the medicament container. The energy storage member can produce a force on a proximal end portion of the actuation rod sufficient to move the distal end portion of the actuation rod within the medicament container. This can convey at least a portion of a substance from the medicament container via the needle when a distal tip of the needle is disposed within a first region of a target location. The force is insufficient to move the distal end portion of the actuation rod within the medicament container when the distal tip of the needle is disposed within a second region of the target location.

公开(公告)号：US20170333416A1

公开(公告)日：2017-11-23

申请号：US15673073

申请日：2017-08-09

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  A61K47/38 ,  A61K9/00 ,  A61K9/10 ,  A61K31/573 ,  A61M37/00 ,  A61K47/26 ,  A61K47/12 ,  A61K45/06 ,  C07K16/22 ,  A61K9/16 ,  A61K39/00

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20170095369A1

公开(公告)日：2017-04-06

申请号：US15383582

申请日：2016-12-19

Applicant: Clearside Biomedical, Inc.

Inventor： Rafael Victor ANDINO ,  Christopher John BROOKS ,  Vladimir ZARNITSYN ,  Harrison J. WHITE

IPC: A61F9/00 ,  A61M5/32 ,  A61M37/00 ,  A61M5/46

CPC classification number: A61F9/0008 ,  A61M5/3286 ,  A61M5/329 ,  A61M5/3293 ,  A61M5/46 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2210/0612

Abstract: An apparatus includes a microneedle that defines a lumen therethrough. The microneedle has a proximal end portion a distal end portion and a hub portion between the proximal end portion and the distal end portion. The proximal end portion is configured to be coupled to a medicament container, such as, for example a syringe. The portion of the lumen within the proximal end portion has a first diameter. The distal end portion is configured to pierce a target tissue. The portion of the lumen within the distal end portion has a second diameter smaller than the first diameter. The hub portion includes a surface configured to contact the target tissue when the distal end portion is disposed with the target tissue.

公开(公告)号：US20190290485A1

公开(公告)日：2019-09-26

申请号：US16440108

申请日：2019-06-13

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Rafael Victor ANDINO ,  Thomas Edward GODFREY ,  Shelley Eckert HANCOCK ,  Samirkumar PATEL ,  Keleigh Jo STRUDTHOFF ,  Jesse YOO ,  Vladimir ZARNITSYN

IPC: A61F9/00 ,  A61K38/18 ,  A61K45/06 ,  A61K38/39 ,  A61K38/36

Abstract: Devices, methods, and kits for ocular drug delivery are described herein. In some embodiments, a method includes inserting a distal end portion of a puncture member into an eye to define a delivery passageway within the eye. The delivery passageway extends through ha sclera of the eye and a choroid of the eye. The delivery passageway is less than about 1.5 mm. The method further includes conveying a substance into a subretinal space within the eye via the distal end portion of the puncture member.

公开(公告)号：US20180028516A1

公开(公告)日：2018-02-01

申请号：US15454636

申请日：2017-03-09

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  A61K47/26 ,  A61K9/00 ,  A61K9/10 ,  A61M37/00 ,  A61K47/38 ,  A61K47/12 ,  A61K45/06 ,  A61K31/573 ,  C07K16/22 ,  A61K9/16 ,  A61K39/00

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20170112665A1

公开(公告)日：2017-04-27

申请号：US15399239

申请日：2017-01-05

Applicant: Clearside Biomedical, Inc.

Inventor： Rafael Victor ANDINO ,  Vladimir ZARNITSYN ,  Jesse YOO ,  Christopher John BROOKS ,  Trent John KAHUTE ,  Justin William ARSENAULT ,  David Jackson TRETTIN ,  Andrew Kent BAUER ,  Stephanie Elaine LEWIS

IPC: A61F9/00 ,  A61M5/20 ,  A61M5/48 ,  A61M5/32 ,  A61M5/46 ,  A61M37/00 ,  A61J1/20

CPC classification number: A61F9/0017 ,  A61F2250/0007 ,  A61F2250/0069 ,  A61J1/201 ,  A61J1/2055 ,  A61J1/2096 ,  A61M5/2033 ,  A61M5/2053 ,  A61M5/31 ,  A61M5/3293 ,  A61M5/34 ,  A61M5/344 ,  A61M5/346 ,  A61M5/347 ,  A61M5/348 ,  A61M5/349 ,  A61M5/46 ,  A61M5/482 ,  A61M37/0015 ,  A61M2005/31508 ,  A61M2037/0023 ,  A61M2037/0061 ,  A61M2210/0612

Abstract: An apparatus includes a housing coupled to a medicament container, which is coupled to a needle. An injection assembly is disposed within the housing and includes an energy storage member and an actuation rod. A distal end portion of the actuation rod is disposed within the medicament container. The energy storage member can produce a force on a proximal end portion of the actuation rod sufficient to move the distal end portion of the actuation rod within the medicament container. This can convey at least a portion of a substance from the medicament container via the needle when a distal tip of the needle is disposed within a first region of a target location. The force is insufficient to move the distal end portion of the actuation rod within the medicament container when the distal tip of the needle is disposed within a second region of the target location.

公开(公告)号：US20190307606A1

公开(公告)日：2019-10-10

申请号：US16178162

申请日：2018-11-01

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Rafael Victor ANDINO ,  Thomas Edward GODFREY ,  Shelley Eckert HANCOCK ,  Samirkumar PATEL ,  Keleigh Jo MAHN ,  Jesse YOO ,  Vladimir ZARNITSYN

IPC: A61F9/00 ,  A61K9/00

Abstract: Devices, methods, and kits for ocular drug delivery are described herein. An apparatus can include a housing, an energy storage member, a barrel, and a hub. The housing contains the energy storage member. A proximal end portion of the barrel is coupled to a distal end portion of the housing. The barrel is configured to contain medicament and includes at least a portion of a piston and an elastomeric member. The piston is configured to move the elastomeric member within the barrel in response to a force produced by the energy storage member. The hub is coupled to a distal end portion of the barrel. An inner surface of the hub defines a nozzle through which the medicament flows when the elastomeric member moves within the barrel. The nozzle and the energy storage member are collectively configured to produce a fluid jet to access a target location within an eye.